FDA's Overreach on Compounded Peptides FDA Peptide Reclassification 2026: What Researchers Want Are Peptides coming off of the FDA Category 2 list? A legal breakdown Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026: What Researchers Want FDA mulls compounding for peptides previously flagged over safety risks BioSpace